Philips Healthcare: Targeting Healthtech Market Recovery Via Value Creation

Challenges Of Recall Add To Pandemic-induced Pressures

Quality issues relating to a historical acquisition have held back Philips Healthcare’s financial performance in the post-COVID phase, while market competitors have been able to chart a less bumpy path through the tail end of the pandemic. All are facing supply chain and inflationary pressures.

Roy Jakobs
Philips Healthcare CEO Roy Jakobs • Source: Philips Healthcare

On the positive side, Philips Healthcare CEO Roy Jakobs knows how to tough it out.

Three years ago, the company promoted him from chief business leader of personal health to the counterpart role in connected...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

Vigya test infogram - Clone

add a desc test

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Vigya test infogram

add a desc test

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.